Twist Bioscience Reports Second Quarter Fiscal 2019 Financial Results and Highlights Commercial and Operational Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Twist Bioscience Corporation (TWST) Tops Q2 EPS by 4c, Revenues Beat; FY19 Revenue Guidance Above Consensus
April 30, 2019 5:07 PM EDTTwist Bioscience Corporation (NASDAQ: TWST) reported Q2 EPS of ($0.93), $0.04 better than the analyst estimate of ($0.97). Revenue for the quarter came in at $13.56 million versus the consensus estimate of $12.02 million.
We continue to post strong topline growth as we extend our reach and diversify our revenue stream from our synbio customers, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist. For NGS, we continue to expand our base of customers rapidly, adding several in production and a larger number in pilot. Importantly, we... More
